Exploring The Principles of Pharmacogenomic Decision Making in Oncology

Activity Details
  • Credit Type: CPE
  • Credit Amount: 1.00
  • Cost: Free
  • Release: Feb 1, 2019
  • Expires: Sep 5, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    (1 Rating)
Didin't officially launch until November 20, 2019


Esther Black Esther Black, PhD
Vice Chair & Associate Professor, Department of Pharmaceutical Sciences
University of Kentucky College of Pharmacy
Lexington, Kentucky

Needs Statement

Personalized medicine is more frequently used and often involves identification of specific genotypes and interpretation of the clinical impact. Many practitioners have not experienced the didactic education to interpret and implement gene/drug guidelines.

Pharmacogenomics is a powerful tool to improve patient outcomes:

  • Improve efficacy
    • New drug targets
    • Adjust dose for high clearance
  • Decrease toxicity
    • Adjust dose for poor clearance
    • Marker of inefficacy

We can address this need by utilizing a continuing education effort to provide the basic science behind appropriate interpretation and implementation of gene/drug guidelines.

Target Audience



Upon completion of this activity, participants will be able to:
1. Review of  genetic terms and nomenclature, and how genetic variation can influence inter-individual variability in pharmacokinetics (PK), pharmacodynamics (PD), and adverse effects (AE) of therapeutic interventions.
2. Describe how to use evidence-based information to make individualized medication recommendations based on pharmacogenomic test results and communicate these recommendations to a health care team.
3. Discuss how to educate patients and health care professionals about the tenets of clinical pharmacogenomics, including ethical, legal, and social implications of pharmacogenomic testing.


ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-18-177-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Faculty Disclosure

No speakers or planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.